144510.KQ
GC Cell Corporation
KOE · Healthcare · Biotechnology · KR
KRW 14,760.00
+7.74%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 162.0B | 165.5B | 174.5B | 187.5B | 236.1B |
| Cost of Revenue | 135.5B | 139.4B | 141.4B | 132.4B | 139.2B |
| Gross Profit | 26.5B | 26.1B | 33.1B | 55.1B | 96.9B |
| Operating Expenses | |||||
| R&D Expense | 12.8B | 18.0B | 25.2B | 24.7B | 26.4B |
| SG&A Expense | 6.6B | 8.4B | 8.2B | 9.8B | 7.9B |
| General & Admin Expense | 2.7B | 3.7B | 3.6B | 4.5B | 2.5B |
| Selling & Marketing Expense | 3.9B | 4.7B | 4.6B | 5.2B | 5.4B |
| Other Expenses | 21.1B | 13.6B | 19.7B | 16.6B | 18.3B |
| Total Operating Expenses | 37.4B | 39.9B | 53.1B | 51.1B | 52.7B |
| Cost and Expenses | 172.8B | 179.3B | 194.5B | 183.5B | 191.8B |
| Operating Income (EBIT) | (10.8B) | (13.8B) | (20.0B) | 4.1B | 44.3B |
| Non-Operating | |||||
| Interest Income | 511.1M | 568.5M | 584.5M | 806.5M | 886.2M |
| Interest Expense | 4.7B | 4.8B | 4.9B | 3.4B | 2.5B |
| Net Interest Income | (4.2B) | (4.2B) | (4.3B) | (2.6B) | (1.6B) |
| Other Non-Op Income/Expense | (216.7B) | (245.1B) | (58.6B) | (11.5B) | (7.8B) |
| Non-Operating Income (excl Interest) | 231.7B | — | 53.7B | 8.1B | 5.3B |
| EBT (Pre-Tax Income) | (227.6B) | (258.9B) | (78.6B) | (7.5B) | 36.5B |
| Income Tax Expense | 4.7B | 57.6M | (2.8B) | (7.5B) | 10.8B |
| Bottom Line | |||||
| Net Income | (232.3B) | (258.9B) | (73.9B) | (174.0M) | 25.0B |
| Earnings from Cont. Ops | (232.3B) | (258.9B) | (75.7B) | 79.1M | 25.7B |
| Earnings from Discont. Ops | — | — | — | — | (1.5B) |
| Bottom Line Net Income | (232.7B) | (258.9B) | (73.9B) | (174.0M) | 25.0B |
| Per Share | |||||
| Basic EPS | (₩15,443) | (₩17,203) | (₩4,916) | (₩12) | ₩1,664 |
| Diluted EPS | (₩15,443) | (₩17,203) | (₩4,916) | (₩12) | ₩1,663 |
| Revenue Per Share | ₩11,153 | ₩10,997 | ₩11,605 | ₩12,933 | ₩15,721 |
| Shares | |||||
| Basic Shares Outstanding | 14.5M | 15.1M | 15.0M | 14.5M | 15.0M |
| Diluted Shares Outstanding | 14.5M | 15.1M | 15.0M | 15.0M | 15.0M |
| Profitability Metrics | |||||
| EBITDA | (7.0B) | 1.7B | (57.7B) | 11.6B | 52.6B |
| D&A | 15.1B | 15.5B | 16.0B | 15.6B | 13.6B |
| EBIT | (22.2B) | (13.8B) | (73.7B) | (4.1B) | 39.0B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026